Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - AccuredReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crinetics Pharmaceuticals (CRNX) Non-Current Deferred Tax Liability (2019 - 2024)

Crinetics Pharmaceuticals has reported Non-Current Deferred Tax Liability over the past 4 years, most recently at $9.8 million for Q4 2024.

  • For Q4 2024, Non-Current Deferred Tax Liability changed 0.49% year-over-year to $9.8 million; the TTM value through Dec 2024 reached $9.8 million, changed 0.49%, while the annual FY2024 figure was $9.8 million, 0.49% changed from the prior year.
  • Non-Current Deferred Tax Liability for Q4 2024 was $9.8 million at Crinetics Pharmaceuticals, roughly flat from $9.8 million in the prior quarter.
  • Over five years, Non-Current Deferred Tax Liability peaked at $9.8 million in Q4 2023 and troughed at $453000.0 in Q4 2022.
  • A 3-year average of $6.7 million and a median of $9.8 million in 2024 define the central range for Non-Current Deferred Tax Liability.
  • Biggest five-year swings in Non-Current Deferred Tax Liability: soared 2063.13% in 2023 and later dropped 0.49% in 2024.
  • Year by year, Non-Current Deferred Tax Liability stood at $453000.0 in 2022, then soared by 2063.13% to $9.8 million in 2023, then fell by 0.49% to $9.8 million in 2024.
  • Business Quant data shows Non-Current Deferred Tax Liability for CRNX at $9.8 million in Q4 2024, $9.8 million in Q4 2023, and $453000.0 in Q4 2022.